Inhaled glucocorticoids and acute asthma: therapeutic breakthrough or nonspecific effect?

Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):677-8. doi: 10.1164/ajrccm.157.3.ed01-98.
No abstract available

Publication types

  • Editorial
  • Research Support, U.S. Gov't, P.H.S.
  • Comment

MeSH terms

  • Acute Disease
  • Administration, Inhalation
  • Adrenergic beta-Agonists / administration & dosage
  • Adrenergic beta-Agonists / therapeutic use
  • Albuterol / administration & dosage
  • Albuterol / therapeutic use
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use*
  • Asthma / drug therapy*
  • Bronchodilator Agents / administration & dosage
  • Bronchodilator Agents / therapeutic use
  • Fluocinolone Acetonide / administration & dosage
  • Fluocinolone Acetonide / analogs & derivatives*
  • Fluocinolone Acetonide / pharmacology
  • Fluocinolone Acetonide / therapeutic use
  • Forced Expiratory Volume / drug effects
  • Genes, MHC Class II / drug effects
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / pharmacology
  • Glucocorticoids / therapeutic use*
  • Humans
  • Microcirculation / drug effects
  • Peak Expiratory Flow Rate / drug effects
  • Receptors, Glucocorticoid / drug effects
  • Transcription, Genetic / drug effects
  • Vasoconstrictor Agents / pharmacology

Substances

  • Adrenergic beta-Agonists
  • Anti-Inflammatory Agents
  • Bronchodilator Agents
  • Glucocorticoids
  • Receptors, Glucocorticoid
  • Vasoconstrictor Agents
  • Fluocinolone Acetonide
  • flunisolide
  • Albuterol